Dong-A ST Achieves Record-High Q2 Sales of KRW 207.8 Billion... Operating Profit Up 170%
Balanced Growth in ETC, International Business, and Digital Healthcare
Drives Revenue Expansion
Dong-A ST announced on July 27 that, on a separate financial statement basis, sales for the second quarter of this year reached KRW 207.8 billion, up 17.2% year-on-year, marking the highest quarterly sales in the company's history.
Operating profit for the same period rose by 170.4% to KRW 10.9 billion. The company explained that profitability improved by maintaining a cost ratio similar to the same period last year, despite increased sales of newly introduced products.
Dong-A ST stated that balanced growth across all business divisions—including ETC (ethical drugs), international business, and digital healthcare—drove the overall increase in sales.
By segment, ETC sales rose 15.2% to KRW 148.6 billion. The steady growth of core products and higher sales of newly introduced items contributed to this performance. The company expects additional revenue growth in the second half with the planned launch of Excopri.
International business sales increased 20.9% to KRW 46.9 billion, supported by growth in sales of products such as Bacchus and Dabepeotin Alpha.
Digital healthcare sales soared 208% to KRW 3.2 billion. The increase was mainly attributed to higher sales of HiCardi, and the company plans to sustain this momentum by launching the new HiCardi M350 in the second half.
In the research and development (R&D) division, core pipeline developments are underway, with research outcomes released through academic presentations.
The DA-1241 treatment for MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes, developed by the US affiliate Metavia, has completed its global Phase 2a clinical trials. The obesity treatment DA-1726 is undergoing a global Phase 1, part 3 clinical trial to confirm safety and optimize tolerance at higher dosages based on a dose-escalation strategy. The tau aggregation inhibitor DA-7503 and the immuno-oncology drug DA-4505 are both in Phase 1 clinical trials in Korea.
Dong-A ST and its subsidiary Aptys presented ten preclinical research results on their oncology pipeline—including the PARP7 inhibitor, EGFR-targeting protein degrader, and bispecific antibody-drug conjugate (ADC)—at the American Association for Cancer Research (AACR). At the Alzheimer's Association International Conference (AAIC), the company disclosed preclinical research results for the GPX4 activator DA-7505 and the tau aggregation inhibitor DA-7503.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Dong-A ST representative said, "We achieved record-high quarterly sales driven by balanced growth across ETC, international business, and digital healthcare divisions. We will continue to strengthen business competitiveness and R&D capabilities to advance as a global healthcare company."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.